Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.07 USD
+0.14 (3.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.02 -0.05 (-1.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AQST 4.07 +0.14(3.56%)
Will AQST be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Other News for AQST
Buy Rating Affirmed for Aquestive Therapeutics Following FDA Approval and Growth Prospects
Aquestive wins FDA approval for anti-seizure therapy Libervant
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
OPI, RVNC and AQST are among after hour movers
Largest borrow rate increases among liquid names